Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Myorisan® (isotretinoin capsules, USP) 10 mg, 20 mg, 30 mg, 40 mg
Medication labelWhy this: Advisory · dailymed-prescription
Myorisan ® is indicated for the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. “Severe,” by definition,2 means “many” as opposed to “few or several” nodules. Because of significant adverse effects associated with its use, Myorisan ® should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, Myorisan ® is indicated only for those patients who are not pregnant, because Myorisan ® can cause life-threatening birth defects (see Boxed CONTRAINDICATIONS AND WARNINGS ). A single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients.1,3,4 If a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off Myorisan ® . The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth (see WARNINGS: Skeletal: Bone Mineral Density, Hyperostosis, Premature Epiphyseal Closure ).
- generic_name
- isotretinoin
- product_names
- isotretinoin
- ndc
- 61748-301, 61748-302, 61748-303, 61748-304, 61748-301-13, 61748-301-11, 61748-301-01, 61748-302-13, 61748-302-11, 61748-302-01, 61748-303-13, 61748-303-11, 61748-303-01, 61748-304-13, 61748-304-11, 61748-304-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en